Lundbeck steering towards weak Q4 despite Covid-19 cutbacks
Although the Covid-19 pandemic allows Lundbeck to cut back on a long list of expenses, it puts pressure on other business areas, such as the migraine drug Vyepti. All in all, Q4 seems to be at the weaker end of the scale.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The fiscal report for Lundbeck's Q3 is something of a mixed bag. Whereas the Danish pharmaceutical company is delivering better results than expected and coming out on the other side of Q3 with decent figures, this picture has more nuances when scrutinized closely.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
